Trial Profile
Recurrent Embolism Lessened by Rivaroxaban, an Anti-Xa Agent of Early Dosing for Acute Ischemic Stroke and Transient Ischemic Attack With Atrial Fibrillation Study (RELAXED)
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 29 Nov 2021
Price :
$35
*
At a glance
- Drugs Rivaroxaban (Primary)
- Indications Stroke; Transient ischaemic attacks
- Focus Adverse reactions; Therapeutic Use
- Acronyms RELAXED
- 17 Nov 2021 Status changed from recruiting to completed.
- 17 Nov 2021 Results of this post-hoc analysis assessing the association between bridging therapy with heparin before starting rivaroxaban and clinical outcomes after ischemic stroke or transient ischemic attack (TIA) in patients with non-valvular atrial fibrillation (NVAF) published in the Circulation Journal
- 14 Jul 2014 New trial record